Measuring and interpreting the selectivity of protein kinase inhibitors
about
Tapentadol: Can It Kill Two Birds with One Stone without Breaking Windows?Glycogen Synthase Kinase-3 (GSK-3)-Targeted Therapy and ImagingCrystal structure of a bacterial phosphoglucomutase, an enzyme involved in the virulence of multiple human pathogensSpecific CLK Inhibitors from a Novel Chemotype for Regulation of Alternative SplicingA comparison of protein kinases inhibitor screening methods using both enzymatic activity and binding affinity determinationSelectivity Profiling and Biological Activity of Novel β-Carbolines as Potent and Selective DYRK1 Kinase InhibitorsDiscoidin domain receptors in disease.An inhibitor's-eye view of the ATP-binding site of CDKs in different regulatory states.A theoretical entropy score as a single value to express inhibitor selectivity.Probing the probes: fitness factors for small molecule tools.Development and strategies of VEGFR-2/KDR inhibitors.Application of a peptide-based assay to characterize inhibitors targeting protein kinases from yeast.Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity.Stimulus-dependent differences in signalling regulate epithelial-mesenchymal plasticity and change the effects of drugs in breast cancer cell lines.The use of novel selectivity metrics in kinase research.Studies on [5,6]-Fused Bicyclic Scaffolds Derivatives as Potent Dual B-RafV600E/KDR Inhibitors Using Docking and 3D-QSAR Approaches.Progress towards a public chemogenomic set for protein kinases and a call for contributions.(1S,2E,4S,7E,11E)-2,7,11-Cembratriene-4,6-diol semisynthetic analogs as novel c-Met inhibitors for the control of c-Met-dependent breast malignancies.Innovative computer-aided methods for the discovery of new kinase ligands.Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Identification of cellular targets involved in cardiac failure caused by PKI in oncology: an approach combining pharmacovigilance and pharmacodynamics.Comparison of the effects of two kinase inhibitors, sorafenib and dasatinib, on chronic lymphocytic leukemia cells.Synthesis and Biological Evaluation of Pyrazolo[1,5-a]pyrimidine Compounds as Potent and Selective Pim-1 Inhibitors.Exploiting Atropisomerism to Increase the Target Selectivity of Kinase Inhibitors.Inhibition of PIP4Kγ ameliorates the pathological effects of mutant huntingtin protein.Demonstrating In-Cell Target Engagement Using a Pirin Protein Degradation Probe (CCT367766).Quantitative, Wide-Spectrum Kinase Profiling in Live Cells for Assessing the Effect of Cellular ATP on Target Engagement.Development of a homogenous high-throughput assay for inositol hexakisphosphate kinase 1 activity.Understanding inhibitor resistance in Mps1 kinase through novel biophysical assays and structures.A Chemical Probe Strategy for Interrogating Inhibitor Selectivity Across the MEK Kinase Family.Enhancing the selectivity of kinase inhibitors in oncology: a chemical biology perspective.Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy.New potential inhibitors of mTOR: a computational investigation integrating molecular docking, virtual screening and molecular dynamics simulation.Computer simulation based selection of optimal monomer for imprinting of tri-O-acetiladenosine in polymer matrix: vacuum calculations.Targeting IKKβ in Cancer: Challenges and Opportunities for the Therapeutic Utilisation of IKKβ InhibitorsIdentification and antitumor activity of a novel inhibitor of the NIMA-related kinase NEK6
P2860
Q26740394-093414CF-771A-4BA0-9BA3-C30EB1F02893Q26768475-A8E55283-626C-4BCA-8580-138B01B5820CQ27666625-693DAADE-69EA-4232-9BDA-661B6F532636Q27666758-042A71D5-2038-47B1-9DD7-49AE111081CCQ28539535-2C0185B0-86BD-4C38-A347-F11B025A31C6Q28546672-DD14C467-9497-442A-B7A4-20F9F7BADE2AQ33605357-F64C284F-9809-4DDB-8B5C-91F51F192C57Q33797218-B3894453-774E-4B06-BB7E-847889C5428DQ33870615-6796AA32-81CC-41D9-9095-7BAEC9938A31Q34001269-336437D9-7046-4A43-9888-1F52749814ACQ34436101-3B9FA9D3-47BD-4311-B984-FF44891115BBQ35124410-5DE4DE06-35BD-4101-BC2D-BB51A0D070AAQ35591349-15469872-4B9A-4CD1-8269-DC7210BDD6D3Q35610049-8428D6AA-C438-4760-90AB-16A4E1C44488Q36240657-60C765E7-C683-4862-A3F2-C3A68CC7101DQ36247419-C3E72819-2F90-4D4C-BB2A-10E623DB23E2Q38646648-27978C28-5F17-4382-84C0-55A4B0A582FDQ38737669-1194503F-8279-4528-8105-D4DA02E5345EQ38814898-BCDD711C-BDEA-4AE2-A7A9-C5AB806BC247Q38989220-0778902A-5C2E-4B77-830C-E68DE0786F53Q39014995-A099AFB1-7C38-4F14-950F-DE8628374C9BQ39305589-96488F56-0560-4D2D-93D9-4FCB3ED181C2Q42101186-D6F9502B-7DAE-4BC4-8371-D9E397175DA1Q46152995-EF76F822-3AAB-45DE-AAAD-5F2964B2911FQ46236725-58E3F9A5-AB7C-40A4-A8BC-3FDE3FC7C835Q47294366-321AF9EF-593E-4C1D-A8CB-F96A63A5908CQ47700032-FD0725AC-F351-460A-860B-7836C6BB083CQ47944803-73C9CED6-721D-4B40-A394-761F3C4681CAQ48095774-D78DD771-18D1-49F5-804D-254D40C58A6CQ48160590-DC80E256-C21A-478B-8066-AB3D18F103F7Q48207016-F7F1CEB0-CB37-49A4-A0EB-F2CFE115E8ADQ49536215-1D4328E7-CAFC-4B9E-9940-FD5261FFBA24Q52809378-3192622A-DC3D-4985-85A1-5C0F5510946EQ54487838-B059629A-0B99-417C-9A53-8424016081B1Q57167736-34337ACD-E6CA-45CC-9EB2-DB07684B1CBCQ58098901-4E4A4302-12FC-4ED2-BE54-00F0DC356C9C
P2860
Measuring and interpreting the selectivity of protein kinase inhibitors
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Measuring and interpreting the selectivity of protein kinase inhibitors
@en
Measuring and interpreting the selectivity of protein kinase inhibitors.
@nl
type
label
Measuring and interpreting the selectivity of protein kinase inhibitors
@en
Measuring and interpreting the selectivity of protein kinase inhibitors.
@nl
prefLabel
Measuring and interpreting the selectivity of protein kinase inhibitors
@en
Measuring and interpreting the selectivity of protein kinase inhibitors.
@nl
P2860
P1476
Measuring and interpreting the selectivity of protein kinase inhibitors
@en
P2093
Ian Collins
Lynette A Smyth
P2860
P2888
P304
P356
10.1007/S12154-009-0023-9
P577
2009-06-06T00:00:00Z